Why the study?
Does intravenous erythromycin lactobionate cause QT prolongation and torsades de pointes in inpatients?
Does intravenous erythromycin lactobionate cause QT prolongation and torsades de pointes in inpatients?
Intravenous erythromycin commonly causes significant QT prolongation, especially in patients with underlying heart disease, though torsades de pointes remains a rare complication.
Answers are grounded in this paper and cite their sources.
May warrant QT monitoring with IV erythromycin; leaves open the TdP risk in broader populations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Oberg et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: